


COMMON BID CUM APPLICATION FORM		GREENSIGNAL BIO PHARMA LIMITED - INITIAL PUBLIC OFFER - NR Regd and Corp. Off.: Old No. 5, New No. 13/A-3 Sai Niketan Circular Road, United India Colony, Kodambakkam, Chennai 600 024, Tamil Nadu, India. Tel: +91 44 2472 2244; Facsimile: +91 44 2472 2233; Website: http://www.gsbpl.com ; CIN: U24232TN2005PLC058068		FOR NON-RESIDENTS, INCLUDING ELIGIBLE NRIs, FIIs FPIs OR FVCIs, ETC APPLYING ON A REPATRIATION BASIS																																																																																																										
<div><div>To, The Board of Directors GREENSIGNAL BIO PHARMA LIMITED</div></div>		<div><div>BOOK BUILT OFFER</div><div>ISIN - INE811U01010</div></div>		<div>Bid Cum Application Form No.</div> <div></div>																																																																																																										
<div>Syndicate Member's Stamp & Code</div> <div></div> <div>Sub-Broker's / Sub-Agent's Stamp & Code</div> <div></div> <div>Bank Branch Serial No.</div> <div></div>		<div>Broker's / SCSB / CDP / RTA Stamp & Code</div> <div></div> <div>Escrow Bank / SCSB Branch Stamp & Code</div> <div></div> <div>SCSB Serial No.</div> <div></div>		<div>1. Name & Contact Details of Sole/First Bidder</div> <div>Mr./Ms./M/s.</div> <div></div> <div>Address</div> <div></div> <div>Email</div> <div></div> <div>Tel. No (with STD code) / Moblie</div> <div></div> <div>2. PAN of Sole / First Bidder</div> <div></div>																																																																																																										
<div>3. Bidder's Depository Account Details <input type="checkbox"/> NSDL <input type="checkbox"/> CDSL</div> <div></div> <div>For NSDL enter 8 Digit DP ID followed by 8 Digit Client ID / For CDSL enter 16 Digit Client ID.</div> <div>4. Bid Options (Only Retail individual Bidders and Eligible Employees Bidding in the Employee Reservation Portion can Bid at "Cut-off")</div> <table><thead><tr><th rowspan="3">Bid Options</th><th colspan="8" rowspan="2">No. of Equity Shares Bid (In Figures) (Bids must be in multiples of Bid Lot as advertised)</th><th colspan="8">Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1/- only) (In Figures)</th><th rowspan="3">"Cut-off" (Please (✓) tick)</th><th rowspan="3">5. CATEGORY</th></tr><tr><th colspan="3">Bid Price</th><th colspan="3">Retail Discount</th><th colspan="3">Net Price</th></tr><tr><th>8</th><th>7</th><th>6</th><th>5</th><th>4</th><th>3</th><th>2</th><th>1</th><th>3</th><th>2</th><th>1</th><th>3</th><th>2</th><th>1</th><th>3</th><th>2</th><th>1</th></tr></thead><tbody><tr><td>Option 1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td><input type="checkbox"/></td><td>Retail Individual Bidder</td></tr><tr><td>(OR) Option 2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td><input type="checkbox"/></td><td>Non Institutional Bidder</td></tr><tr><td>(OR) Option 3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td><input type="checkbox"/></td><td>QIB</td></tr></tbody></table>						Bid Options	No. of Equity Shares Bid (In Figures) (Bids must be in multiples of Bid Lot as advertised)								Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1/- only) (In Figures)								"Cut-off" (Please (✓) tick)	5. CATEGORY	Bid Price			Retail Discount			Net Price			8	7	6	5	4	3	2	1	3	2	1	3	2	1	3	2	1	Option 1																		<input type="checkbox"/>	Retail Individual Bidder	(OR) Option 2																		<input type="checkbox"/>	Non Institutional Bidder	(OR) Option 3																		<input type="checkbox"/>	QIB
Bid Options	No. of Equity Shares Bid (In Figures) (Bids must be in multiples of Bid Lot as advertised)														Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1/- only) (In Figures)										"Cut-off" (Please (✓) tick)	5. CATEGORY																																																																																				
									Bid Price			Retail Discount			Net Price																																																																																															
	8	7	6	5	4	3	2	1	3	2	1	3	2	1	3	2	1																																																																																													
Option 1																		<input type="checkbox"/>	Retail Individual Bidder																																																																																											
(OR) Option 2																		<input type="checkbox"/>	Non Institutional Bidder																																																																																											
(OR) Option 3																		<input type="checkbox"/>	QIB																																																																																											

7. Payment Details

PAYMENT OPTION : Full Payment ☐ Part Payment ☒

Amount Blocked (₹ in Figures)

(₹ in words)

ASBA Bank A/c No.

Bank Name & Branch

I/WE (ON BEHALF OF JOINT APPLICANTS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS BID CUM APPLICATION FORM AND THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC OFFERS ("GID") AND HEREBY AGREE AND CONFIRM THE 'BIDDERS UNDERTAKING' AS GIVEN OVERLEAF. I/WE (ON BEHALF OF JOINT APPLICANTS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THE BID CUM APPLICATION FORM GIVEN OVERLEAF.

8A. Signature of Sole / First Bidder

Date: _____, 2016

8 B. Signature of ASBA Bank Account Holder(s) (As Per Bank Records)


I/We authorize the SCSB to do all acts as are necessary to make the Application in the Offer

1)

2)

3)

Syndicate Member/Broker / SCSB / CDP / RTA STAMP (Acknowledging upload of Bid in Stock Exchange system)

	GREENSIGNAL BIO PHARMA LIMITED - INITIAL PUBLIC OFFER - NR	Acknowledgement Slip for Syndicate Member Broker/SCSB/CDP/RTA	Bid Cum Application Form No.		
TEAR HERE					
DPID / CLID: 		PAN of Sole / First Bidder: 			
Amount Blocked (₹ in figures): 		ASBA A/c. No.: 		Stamp & Signature of SCSB Branch <div style="border: 1px solid black; width: 100px; height: 100px; margin: 0 auto;"></div>	
Bank & Branch: 					
Received from Mr./Ms./M/s.: 					
Telephone / Mobile: 		Email: 			
TEAR HERE					
GREENSIGNAL BIO PHARMA LIMITED - INITIAL PUBLIC OFFER - NR	Option 1	Option 2	Option 3	Stamp & Signature of Syndicate Member/ Registered Broker / SCSB / CDP / RTA <div style="border: 1px solid black; width: 100px; height: 100px; margin: 0 auto;"></div>	Name of Sole / First Bidder
	No. of Equity Shares				
	Bid Price				
	Amount Blocked (₹)				
	ASBA Bank A/c No.: 				Acknowledgment Slip for Bidder
Bank & Branch: 					
				Bid Cum Application Form No.	

IN THE NATURE OF ABRIDGED PROSPECTUS – MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

BIDDER'S UNDERTAKING FOR BID CUM APPLICATION FORM

(IN CASE OF A JOINT APPLICATION, THE CONFIRMATIONS, AUTHORIZATIONS, UNDERTAKINGS AND REPRESENTATIONS MADE BY THE FIRST APPLICANT WILL BE DEEMED TO HAVE BEEN MADE ON BEHALF OF ALL JOINT APPLICANTS. THE FIRST APPLICANT SHALL BE LIABLE FOR ALL THE OBLIGATIONS ARISING OUT OF THE OFFER OF EQUITY SHARES.)

On the basis of the RHP dated October 13, 2016 and having studied the attached details as per the Abridged Prospectus, I/we hereby apply for allotment to me/us of the Equity Shares in the Offer upto my/our Bids for maximum number of Equity Shares at or above the Offer Price, to be discovered through Book Building Process. I/We hereby confirm that I am/we are eligible persons to invest in this Offer in accordance with applicable laws. I/We agree to accept the Equity Shares Bid for, or such lesser number as may be allotted to me/us subject to the terms of the RHP, the Bid cum Application Form, the Abridged Prospectus, GID and other applicable laws. I/We undertake that I/we will sign all such other documents and do all such acts, if any, necessary on my/our part to enable me/us to be registered as the holder(s) of the Equity Shares which may be allotted and to register my/our address as given in the depository records. I/We note that in case of QIB Bidders, the (i) SCSBs (for Bids other than the Bids by Anchor Investors); and (ii) the BRLMs and their affiliate Syndicate Members (only in the Specified Locations) have the right to reject Bids at the time of acceptance of Bid cum Application Form provided that the reasons for rejecting the same shall be provided to such Bidder in writing, whereas it has a right to reject it from Non-Institutional Bidders and Retail Individual Bidders based only on technical grounds and/or as specified in the Abridged Prospectus, GID and the RHP. I/We authorize the Company to make the necessary changes in this Bid cum Application Form and the RHP for filing of the Prospectus with the Registrar of Companies without intimation to me/us and use this Bid cum Application Form as the Application Form for the purpose of this Offer.

I/WE CONFIRM THAT: (a) I/We and any customer I/We represent, am/are located outside the United States within the meaning of Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act"); (b) I am/We are not an affiliate of the Company or a person acting on behalf of such affiliate; (c) I am/We are, or at the time the Equity Shares are purchased will be, the beneficial owner(s) of such Equity Shares (d) I am/We are Indian(s) of Indian Origin residing abroad/FPIs/FVCI and that I/We have remitted funds for Equity Shares bid for here in through normal banking channels or out side of the funds held in Non-Resident External (NRE) Account/Foreign Currency Non Resident (FCNR) Account in India and (e) I/We also confirm that I/We are not bidding for Equity Shares as nominee(s) of any person(s) who are not Non Resident Indians.

FOR QIB BIDDERS: We confirm that the Bid Size/Maximum Equity Shares applied for by us do not exceed the relevant regulatory approvals/limits. I/We am/are not prohibited from accessing capital markets under any order/ruling/ judgment of any regulatory, judicial or any other authority, including SEBI or under the provisions of any law, regulation or statute.

Further: 1) In accordance with ASBA process provided in SEBI Regulations and as disclosed in the RHP, I/We authorize (a) the members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centers) or the SCSB or the Collecting RTA or the Collecting DP to do all acts as are necessary to make the Application in the Offer, including uploading my/our Bid, blocking or unblocking of funds in the bank account maintained with the SCSB as specified in the Bid Cum Application Form, transfer of funds to the Public Offer Account on receipt of instruction from Registrar to the Offer, after finalization of Basis of Allotment; and (b) the Registrar to the Offer to issue instruction to the SCSBs to unblock the funds in the specified bank account upon finalization of the basis of Allotment. 2) In case the amount available in the specified bank account is insufficient as per the highest Bid option, the SCSB shall reject the Application. 3) I/we hereby authorize the members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSB or Collecting DP or the Collecting RTA, as the case may be, to make relevant revisions as may be required to be done in the Bid, in the event of a revision of the Price Band.

INSTRUCTION FOR FILING UP THE BID CUM APPLICATION FORM

- Name of Sole/ First Applicant should be exactly the same as it appears in the depository records. In case of joint Bids, only the name of the first Bidder (which should also be the first name in which the beneficiary account is held) should be provided in the Bid cum Application Form.
- The Bid means an 'Indication to make an Offer' and not as 'An Offer'.
- The first Bidder, should mention his/ her PAN allotted under the Income Tax Act, 1961 and any Bid cum Application Form without the PAN is liable to be rejected.
- Based on the PAN, DP ID and Client ID provided by the Bidders, the Registrar will obtain demographic details registered with depository participants to be used for allotment, technical rejections, etc. Hence, Bidders are advised to immediately update any change in their details as appearing on the records of the Depository Participant. Please note that failure to do so could result in failure in allotment of Equity Shares, at the Bidders sole risk and neither the Syndicate member nor the Registrar nor the Collecting RTAs nor the CDPs or the SCSBs nor the Company shall have any responsibility and undertake any liability for the same.
- Bid Lot and Price Band:** The Price Band, discount offered, if any, and the Minimum Bid Lot size will be decided by the Company in consultation with the Selling Shareholders and the BRLM and will be advertised at least five Working Days prior to the Bid/Offer Opening Date in all editions of the English national daily newspaper Financial Express, all editions of the Hindi national daily newspaper Jansatta, and the Chennai Edition of Makkal Kural, The Tamil Newspaper with wide circulation at the place where our Registered Office is located, each of wide circulation in accordance with the SEBI Regulations. In case of revision of the Price Band, the Bid/Offer Period will be extended for at least three additional working days after revision of Price Band subject to the Bid/Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a press release and also by indicating the changes on the terminals of the Syndicate Members and by intimation to SCSBs, Registered Brokers, CDPs and RTA. **Maximum and Minimum Bid Size:** In case of resident Retail Individual Bidders, such number of shares such that the Bid Amount does not exceed ₹ 2,00,000. Bids at the Cut-Off Price indicate their agreement to purchase the Equity Shares at the Offer Price, as determined at the completion of the Book Building Process. In case of Non-Institutional Bidders and QIB Bidders, the minimum Bid size shall be such number of shares such that bid amount exceeds ₹ 2,00,000. The maximum Bid by any investor should not exceed the investment limits prescribed for them by applicable laws.
- Please tick Category as applicable to ensure proper upload of Bids in the Stock Exchange system.
- Please tick investor status as applicable. Please ensure investor status is updated in your Depository records.
- Total Amount payable must be calculated for the highest of three options, at Bid Price, at the time of the submission of the Bid cum Application Form. **Cheques/Demand Draft/Cash/stock invest/ money orders/postal orders will not be accepted.** All NRI Bidders bidding on a repatriation basis by using the Non-Resident Forms are required to authorize their SCSB to block their NRE/ FCNR ASBA Accounts, and all NRI Bidders bidding on a non-repatriation basis by using Resident Forms are required authorize their SCSB to block their Non-Resident Ordinary (NRO) accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form. The NRI Applicants can obtain the Bid cum Application Form from the Company's Registered Office or from any of the members of the Syndicate or Collecting DPs or Collecting RTAs or Registered Brokers from their Offices. Bidders please ensure that your Bank is an SCSB and has notified an SCSB Branch in the city where Bid cum Application Form is being submitted.
- Only the first Bidder is required to sign the Bid cum Application Form /Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Signature of ASBA Bank Account Holder is mandatory.
- Other Instructions:** a. Bids must be made only in the prescribed Bid cum Application Form. b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the members of the Syndicate, Registered Brokers, CDPs, Collecting RTAs, and/or SCSBs will not be liable for errors in data entry due to incomplete or illegible Bid cum Application Forms. c. Ensure that all applicable documents in support of the Bid are attached with the Application Form.
- The applicants may note that in case the DP ID, Client ID and PAN mentioned in the Bid cum Application Form and entered into the electronic bidding systems of the Stock Exchanges do not match with the DP ID, Client ID and PAN available in the Depository database, the Bid Cum Application Form is liable to be rejected.
- The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold within the United States (as defined in Regulation S of the U.S. Securities Act), except pursuant to an exemption form, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. There will not and is not currently intended to be any public offering of securities in the United States. Accordingly, the Equity Shares are only being offered and sold outside the United States in reliance on Regulation S of the U.S. Securities Act and the applicable laws of the jurisdiction where these offer and sales offer.

Note : Terms used but not defined herein shall have the meaning assigned to such terms in the RHP.

TEAR HERE

	COMPANY CONTACT DETAILS	REGISTRAR CONTACT DETAILS
	GREENSIGNAL BIO PHARMA LIMITED CIN: U24232TN2005PLC058068 Registered and Corporate Office: Old No. 5, New No. 13/A-3 Sai Niketan Circular Road, United India Colony, Kodambakkam, Chennai 600 024, Tamil Nadu, India. Tel: +91 44 2472 2244; Facsimile: +91 44 2472 2233; Email: cs@gsbpl.com; Website: http://www.gsbpl.com; Company Secretary and Compliance Officer: Ms. S. Rathna Prabha	BIGSHARE SERVICES PRIVATE LIMITED E2 Ansa Industrial Estate, Sakivihar Road, Sakinaka Andheri East, Mumbai – 400 072 Tel: + 91 22 4043 0200; Facsimile: + 91 22 2847 5207 Email: ipo@bigshareonline.com; Investor Grievance Email: investor@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Ashok Shetty SEBI Registration No.: INR000001385

This is an abridged prospectus containing salient features of the Red Herring Prospectus dated October 13, 2016 (RHP). You are encouraged to read greater details available in the RHP.

THIS DOCUMENT CONSISTS OF FOUR PAGES OF APPLICATION FORM ALONG WITH INSTRUCTIONS AND SIX PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.

You may obtain a physical copy of the Bid cum Application form and the RHP from Stock Exchanges, Members of the Syndicate, Registered Brokers, Collecting Depository Participants, Registrar to the Offer, Registrar and Share Transfer Agents, Underwriters, Bankers to the Offer and Self Certified Syndicate Banks. You may also download the RHP from the websites of Securities and Exchange Board of India ("SEBI"), the Global Co-ordinator & Book Running Lead Manager ("GCBRLM") and BSE Limited and National Stock Exchange of India Limited (collectively "Stock Exchanges") i.e. www.sebi.gov.in; www.iob.in; www.nseindia.com and www.bseindia.com. All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.



GREENSIGNAL BIO PHARMA LIMITED

Corporate Identification Number of our Company is U24232TN2005PLC058068

Registered and Corporate Office: Old No. 5, New No. 13/A-3 Sai Niketan, Circular Road, United India Colony, Kodambakkam, Chennai 600 024, Tamil Nadu, India,

Tel: +91 44 2472 2244; **Facsimile** +91 44 2472 2233; **Website:** <http://www.gsbpl.com>;

Company Secretary and Compliance Officer: Ms. S. Rathna Prabha

Tel.: +91 44 2472 2244 Extn. 25; **Facsimile:** +91 44 2472 2233; **Email:** cs@gsbpl.com;

PROMOTERS OF THE COMPANY: MR. P. SUNDARAPARIPOORANAN AND DR. P. MURALI

OFFER DETAILS, LISTING AND PROCEDURE

PUBLIC OFFER OF 1,45,79,560 EQUITY SHARES OF A FACE VALUE OF ₹ 10 EACH (THE "EQUITY SHARES") OF GREENSIGNAL BIO PHARMA LIMITED (THE "COMPANY") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE INCLUDING A PREMIUM OF ₹ [●] THROUGH AN OFFER FOR SALE BY P. SUNDARAPARIPOORANAN, DR. P. MURALI (P. SUNDARAPARIPOORANAN AND DR. P. MURALI HEREBY COLLECTIVELY REFERRED TO AS "PROMOTER SELLING SHAREHOLDERS"), MALLIKA MURALI (MALLIKA MURALI HEREBY REFERRED TO AS "PROMOTER'S GROUP SELLING SHAREHOLDER"), R. SRINIVASAN AND AVON CYCLES LIMITED (R. SRINIVASAN AND AVON CYCLES LIMITED HEREBY COLLECTIVELY REFERRED AS "PUBLIC SELLING SHAREHOLDERS") (PROMOTER SELLING SHAREHOLDERS, PROMOTER'S GROUP SELLING SHAREHOLDERS AND PUBLIC SELLING SHAREHOLDERS ARE HEREBY COLLECTIVELY REFERRED AS SELLING SHAREHOLDERS) AGGREGATING UPTO ₹ [●] LACS (THE "OFFER"). THE OFFER WILL CONSTITUTE 38% OF THE FULLY DILUTED POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR THE DETAILS OF THE EQUITY SHARES OFFERED BY EACH SELLING SHAREHOLDER, PLEASE SEE THE SECTION "DEFINITIONS AND ABBREVIATIONS – OFFER RELATED TERMS – OFFER" ON PAGE 1. THE FACE VALUE OF EQUITY SHARES IS ₹ 10 EACH.

PRICE BAND FOR THE OFFER SHALL BE DECIDED BY THE COMPANY AND SELLING SHAREHOLDERS IN CONSULTATION WITH BRLM AND WILL ALSO BE ADVERTISED IN ALL EDITIONS OF FINANCIAL EXPRESS (ENGLISH NATIONAL); (II) ALL EDITIONS OF JANSATTA (HINDI NATIONAL), EACH WITH WIDE CIRCULATION, AND CHENNAI EDITION OF MAKAL KURAL, THE TAMIL NEWSPAPER, THE NEWSPAPER WITH WIDE CIRCULATION AT THE PLACE WHERE REGISTERED OFFICE OF COMPANY IS LOCATED, AT LEAST FIVE WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SUCH ADVERTISEMENT SHALL BE AVAILABLE ON THE WEBSITES OF THE BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE").

PROCEDURE

If you wish to know about processes and procedures applicable to public issues, you may request for a copy of the General Information Document from the BRLM or download it from the websites of NSE and BSE at www.nseindia.com and www.bseindia.com and the website of BRLM at www.iob.in

ELIGIBILITY FOR THE OFFER – Regulation 26 (2) of SEBI (ICDR) Regulations, 2009

Bid/Offer Opening Date*	November 09, 2016 (Wednesday)	Initiation of Refunds	November 21, 2016 (Monday)
Bid/Offer Closing Date	November 11, 2016 (Friday)	Credit of Equity Shares to demat account of Allottees	November 21, 2016 (Monday)
Finalisation of Basis of Allotment with the Designated Stock Exchange	On or before November 18, 2016 (Friday)	Commencement of trading of Equity Shares on the Stock Exchanges	November 22, 2016 (Tuesday)

*Our Company, in consultation with the Selling Shareholders and the BRLM, may consider participation by Anchor Investors in accordance with SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period shall be One Working Day prior to the Bid/Offer Date.

IN THE NATURE OF ABRIDGED PROSPECTUS – MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

GENERAL RISKS

Investments in equity and equity related securities involve a degree of risk and investors should not invest any funds in this Offer unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Offer. For taking an investment decision, investors must rely on their own examination of the Issuer and this Offer, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to the section titled “Risk Factors” at Page No. 13 of the Red Herring Prospectus and on Page No. 7 of this Abridged Prospectus.

PRICE INFORMATION OF BRLM

Issue Name	Name of Merchant Banker	+/- change in closing price, [+ / - change in closing benchmark]		
Veto Switchgears and Cables Limited	IOB & Keynote Corporate Services Limited	0.09	1.58	3.96

Notes:

1. All data secured from NSEINDIA.COM –EMERGE
2. Since there is no NSE-SME Bench mark index during the stated period, the change in closing benchmark value has not been given.
3. 30th, 90th, 180th calendar day from listed day have been taken as listing day plus 29, 89 and 179 calendar days except wherever 30th, 90th, 180th calendar is either a holiday or share not traded in which case we have considered the closing date of next traded day.

Name of the BRLM and contact details (Telephone and email id)	INDIAN OVERSEAS BANK , Merchant Banking Division. Tel.: + 91 44 2851 9548/ 2888 9367; + 91 22 2262 2017/2262 2018 Email: mbd@jobnet.co.in ; mbdregu@jobnet.co.in
Name of Syndicate Member	1. Arihant Capital Markets Limited 2. Pantomath Stock Brokers Private Limited
Name of the Registrar to the Offer and contact details (Telephone and email id)	BIGSHARE SERVICES PRIVATE LIMITED Tel: + 91 22 4043 0200; Email: ipo@bigshareonline.com;
Name of Statutory Auditor	M/s. RAJ & RAVI, Chartered Accountants
Name of Credit Rating Agency and the rating or grading obtained, if any	Not Applicable
Name of Debenture Trustee, if any	Not Applicable
Self-Certified Syndicate Banks	The list of banks is available on www.sebi.gov.in/cms/sebi_data/attachdocs/1365051213899.html which is updated from time to time
Non Syndicate Registered Brokers	You can submit Bid cum Application Forms in the Issue to Registered Brokers at the Broker Centres. The details of such Broker Centres along with the names and contact details of the Registered Brokers are available on the respective websites of the Stock Exchanges (www.bseindia.com , www.nseindia.com)
Details regarding website address(es)/link(s) from which the investor can obtain list of registrar to offer and share transfer agents, depository participants and stock brokers who can accept application from investor (as applicable)	The details of the Designated Registrar and Share Transfer Agents locations and Designated Collecting Depository Participant Locations along with their Names and Contact Details are available on the website of the Stock Exchanges (www.bseindia.com , www.nseindia.com)

IN THE NATURE OF ABRIDGED PROSPECTUS – MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

PROMOTERS OF THE COMPANY

The Promoters of the Issuer Company: 1. Mr. P Sundarapariipooranan 2. Dr. P Murali

1. **Mr. P. Sundarapariipooranan** - Aged 46 years is the Promoter of the Company. He is not involved in the day to day management of the Company. He is a resident of India. His Passport Number is Z2823806 and Driving license no. is TN09 19940000268.
2. **Dr. P. Murali** - Aged 43 years, is an Arts Graduate and a Masters in Labour Management. He holds a Doctorate in Management from Madras University. He has about 15 years of experience in Information Technology and Pharmaceutical Productions, Installation, Commissioning, Quality Management, Financial Planning and Human Resources Management. He is the Managing Director of the Company. His Passport Number is Z3257930 and Aadhar no. is 627778201623.

BUSINESS OVERVIEW AND STRATEGY

We are into Vaccine Manufacturing and as on date we produce two products:

1. BCG Vaccine for immunization against Tuberculosis
2. BCG-ONCO for Immunotherapy (Freeze Dried) BP for the treatment of Urinary Bladder Carcinoma and our brand name for the same is 'Urovac'.

Our manufacturing facility is located at No.49, Pappankuppam Village, Gummidipoondi, Tiruvalluvar District - 601 201. The facility is located on a sprawling 1.4 acres of land space, with a build-up area of 35250.96 sq.ft.. Our centre is built as per the WHO standards and HVAC regulations. Apart from the Vaccine Manufacturing Facility, the campus also houses our DSIR approved Research & Development centre. Our Company is Good Manufacturing Practices (GMP) as laid down by World Health Organisation (WHO) certified. Having established ourselves in the Indian vaccines market, we have expanded internationally through organic growth, which is our key focus area for further expansion. Our products are exported to 17 countries, either directly through UNICEF or indirectly, through supply, distribution and other arrangements.

Our major domestic client is Ministry of Health & Family Welfare, Government of India and overseas client is UNICEF. Further, we also export our products to clients present in Indonesia, Nepal. For countries like Nepal, Indonesia we have separate import permits with the concerned countries.

The major clients of our Company are UNICEF and Ministry of Health, Government of India. These two clients constitute nearly 63.86% and 46.67% of the revenues of the Company for the year ended March 31, 2016 and period ended June 30, 2016 respectively.

Strategy

1. **Export Orders**
2. **Increase geographical presence**
3. **Upstream and Downstream processes**
4. **Extensive Follow up with suppliers**
5. **Close follow-up with pipeline manufacturers seeking WHO Pre-Qualification.**

BOARD OF DIRECTORS

Sl. No.	Name	Designation	Experience including current/past position held in other firms
1	Mr. N. Gopalaswami	Chairman	<p>He is a former Chief Election Commissioner of India. He was awarded Padma Bhushan, one of India's highest civilian honours in 2015. He took charge as the Chief Election Commissioner (CEC) of India on June 30, 2006 and retired in April 2009. Prior to his appointment as CEC, he was serving as Union Home Secretary to the Government of India. Presently, he is also the Chairman of Kalakshetra, Chennai and also the President of Vivekananda Educational Society, running a group of schools in and around Chennai.</p> <p>He is a director in Span Divergent Limited and Code Consulting Private Limited</p>

IN THE NATURE OF ABRIDGED PROSPECTUS – MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

Sl. No.	Name	Designation	Experience including current/past position held in other firms
2	<i>Dr. P. Murali</i>	Managing Director	For details please refer to “Promoters of our Company” on page 5 of this Abridged Prospectus.
3	<i>Mr. E. S. Chandrasekaran</i>	Executive Director	He graduated as Bachelor of Engineering and holds a Master’s Degree in Engineering from Madras University. He has also completed his Post Graduate Diploma in Management Studies from Bombay University. He has over 8 years of experience in Planning, Installation, Commissioning of Vaccine Plant and was instrumental in getting WHO – Pre Qualification Certification. He has worked for 32 years in various capacities in Government of India and retired from the rank of Principal Secretary, Government of India.
4	<i>Dr. P. Perumalsamy</i>	Non Executive Independent Director	He pursued Masters in Chemistry in American College and completed Masters in Education from Madurai Kamaraj University. He was awarded Doctorate by Alagappa University, Karaikudi for his research on “Appraisal of Performance Indicators on Effective Schooling”. He served as District Educational Officer through Tamil Nadu Public Service Commission and held post of Joint Director and later as Director of School Education for more than a decade.
5	<i>Mrs. Lakshmi V Iyer</i>	Non Executive Independent Director	She is a qualified Chartered Financial Analyst (CFA). She has worked as Deputy Manager with State Bank of India Funds Management Limited. Later she was with CRISIL as Senior Rating Analyst and later in Societe Generale and Bank of America in Key Managerial Positions. She served as Director, Credit Research for HVB Asset Management, Singapore during the years 2004-2006. Currently, she is an Independent Financial consultant.

OBJECTS OF THE OFFER

The objects of the Offer are to achieve the benefits of listing the Equity Shares on the BSE and the NSE and to carry out the sale of up to 14,579,560 Equity Shares by the Selling Shareholders. Further, our Company expects that the listing of the Equity Shares will enhance our visibility and brand image among our existing and potential customers and provide liquidity to the existing shareholders. The listing of the Equity Shares will also provide a public market for the Equity Shares in India. Our Company will not receive any proceeds of the Offer and all the proceeds will go to the Selling Shareholders.

SHAREHOLDING PATTERN OF THE COMPANY AS ON

Sl. No.	Particulars	Pre-Offer number of shares	% of holding Pre-Offer
1	Promoter & Promoter Group	3,20,56,000	83.55%
2	Public	63,11,275	16.45%
	Total	3,83,67,275	100.00

IN THE NATURE OF ABRIDGED PROSPECTUS – MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

Number of Equity Shares to be sold by Selling Shareholders by way of Offer of Sale

Sl. No.	Name of the Shareholder	Category	No. Of Equity Shares Offered
1	P. Sundaraparipooranan	Promoter	81,69,430
2	P. Murali	Promoter	33,91,980
3	Mallika Murali	Promoter Group	6,24,150
4	Avon Cycles Limited	Public	23,75,000
5	R Srinivasan	Public	19,000
	Total		14,579,560

RESTATEd AUDITED FINANCIALS

Standalone	Quarter ended June 30, 2016	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Total Revenue	1,020.55	2,049.25	660.29	352.80	1,169.80	1,126.58
Profit/Loss before tax and exceptional items	372.55	693.76	(1.29)	(105.91)	(17.17)	(4.98)
Restated Profit/(Loss) from continuing operations	293.09	530.95	(21.33)	(129.71)	(50.01)	(48.11)
Equity Share Capital	3,836.73	1,534.69	1,357.35	1,357.35	1,357.35	1,357.35
Reserves and Surplus	2,129.33	4,138.28	2,365.91	2,221.01	2,350.72	2,400.73
Networth	5,966.06	5,672.97	3,723.26	3,578.36	3,708.07	3,758.08
Basic earnings per share	0.76	1.45	(0.16)	(0.96)	(0.37)	(0.35)
Diluted earnings per share	1.45	1.45	(0.16)	(0.96)	(0.37)	(0.35)
Return on networth (%)	6.14	11.86	(0.84)	(5.09)	(1.87)	(1.76)
Net Asset value per share	12.43	29.17	18.62	18.77	19.73	20.10

INTERNAL RISK FACTORS

Below are the top 5 Risk Factors as per RHP

- We have only two products and if our production of the BCG vaccine, which is the major source of our revenue is stalled or stopped or if there is any impediment in its domestic or overseas sales and distribution it will materially adversely affect our business and profits.*
- Currently, we are producing only two products. BCG Vaccine and BCG – ONCO for Immunotherapy, an immuno therapeutic drug for Urinary Bladder Cancer. Our business, prospects, results of operations and financial condition may be adversely affected if any of these two products in our portfolio do not perform as expected or if competing products become available and gain wider market acceptance.*
- In India, our price is regulated for the BCG vaccine and hence it is imperative for us to solicit markets overseas. Though we are in the process of procuring contracts from various governments and countries there is a high risk that the eventual business may not materialize and we are not able to procure newer overseas markets. In the event we are unable to do so it will materially adversely affect our business.*
- There is an outstanding litigation involving our Company, wherein our Company is involved in a litigation relating to trademark, any adverse decision in said case may affect our Company. In the past also, our Company had been involved in criminal litigations initiated by Central Bureau of Investigation.*
- Our Company has made a Net loss for the preceding four out of five financial years and has made profits only in the year ended March 31, 2016 (out of the past five years). Continual losses will adversely affect our sustainability and business operations.*

IN THE NATURE OF ABRIDGED PROSPECTUS – MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

- A. Total number of outstanding litigations against the Company and amount involved – There is 1 outstanding litigation filed against us and the approximate amount involved is Rs.10 lakhs.**
- B. Brief details of outstanding litigation against the Company and the amount involved.**

Sl. No.	Particulars	Litigation filed by	Current Status	Amount involved (Rs. In lakhs)
1.	Trade Mark related case filed against the Company	Serum Institute of India Private Limited	Pending	Rs. 10 Lakhs

- C. Regulatory Action, if any – disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any – NIL**
- D. Brief details of outstanding criminal proceedings against Promoters – NIL**

ANY OTHER IMPORTANT INFORMATION AS PER BRLM / ISSUER COMPANY – NIL

DECLARATION BY THE COMPANY

We, the Directors, hereby declare and certify that all relevant provisions of the Companies Act (including the rules made thereunder) and the rules, regulations, and guidelines issued by the Government of India or the SEBI, as the case may be, have been complied with and no statement made in the Red Herring Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act or rules, regulations, and guidelines made thereunder, as the case may be. We further certify that all the statements and disclosures in the Red Herring Prospectus are true and correct.

DECLARATION BY THE SELLING SHAREHOLDERS

I, P. Sundaraparipooranan, hereby declare and certify that all statements made, and undertakings provided, in the Red Herring Prospectus about or in relation to myself and the Equity Shares being offered by me in the Offer are true and correct. I assume no responsibility for any of the statements made, or undertakings provided by the Company or any other Selling Shareholder or any expert or any other persons in the Red Herring Prospectus.

I, P Murali, hereby declare and certify that all statements made, and undertakings provided, in the Red Herring Prospectus about or in relation to myself and the Equity Shares being offered by me in the Offer are true and correct. I assume no responsibility for any of the statements made, or undertakings provided by the Company or any other Selling Shareholder or any expert or any other persons in the Red Herring Prospectus.

I, V. A. Deepa, authorised representative of Avon Cycles Limited, hereby declare and certify that all statements made, and undertakings provided, in the Red Herring Prospectus about or in relation to Avon Cycles Limited and the Equity Shares being offered by it in the Offer are true and correct. Avon Cycles Limited assume no responsibility for any of the statements made, or undertakings provided by the Company or any other Selling Shareholder or any expert or any other persons in the Red Herring Prospectus.

I, R. Srinivasan, hereby declare and certify that all statements made, and undertakings provided, in the Red Herring Prospectus about or in relation to myself and the Equity Shares being offered by me in the Offer are true and correct. I assume no responsibility for any of the statements made, or undertakings provided by the Company or any other Selling Shareholder or any expert or any other persons in the Red Herring Prospectus.

I, Mallika Murali, hereby declare and certify that all statements made, and undertakings provided, in the Red Herring Prospectus about or in relation to myself and the Equity Shares being offered by me in the Offer are true and correct. I assume no responsibility for any of the statements made, or undertakings provided by the Company or any other Selling Shareholder or any expert or any other persons in the Red Herring Prospectus.

This page is intentionally left blank

This page is intentionally left blank

IN THE NATURE OF ABRIDGED PROSPECTUS – MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

BIDDER'S UNDERTAKING FOR REVISION FORM

I/We (on behalf of joint applicants, if any) confirm that the Acknowledgement slip for my/our bids are enclosed for the revisions which are being requested. I/We agree to be bound by all the terms & conditions mentioned in the Bid cum Application Form submitted earlier by me/us.

I/We (on behalf of joint applicants, if any) authorise you to reject this Bid Revision Form, in case any of the details of my existing Bids as appearing on the electronic book building system do not tally with the details given in this Revision Form.

INSTRUCTION FOR FILLING UP THE BID REVISION FORM

1. Name of Sole/ First Bidder should be exactly the same as it appears in the depository records.
2. Please ensure that the Bid Options provided are in the same order as that provided in the Bid Cum Application Form submitted earlier.
3. In case there is no change in the particular Bid Option, please write "NO CHANGE". In case you want to cancel the Bid Option, please write "CANCELLED".
4. Total Amount payable must be calculated for the highest of three options, at Net Price, i.e., Bid Price. Total amount to be paid must be calculated net of total amount paid at the time of submission of Bid cum Application Form. Bidders, please ensure that your Bank has notified an SCSB Branch in the city where Application Form is being submitted. **Revision of Bids in case of Revision of Price Band:** In case of an upward revision in the Price Band, Retail Individual Bidders who had Bid at Cut-off Price could either (i) revise their Bid or (ii) shall make additional payment based on the cap of the revised Price Band (such that the total amount i.e., original Bid Amount less discount, if any, plus additional payment does not exceed ₹ 200,000 if the Bidder wants to continue to Bid at Cut-off Price), with the members of the Syndicate/Registered Brokers/RTA/CDPs to whom the original Bid was submitted. In case the total amount (i.e., original Bid Amount less discount, if any, plus additional payment) exceeds ₹ 200,000/-, the Bid will be considered for allocation under the Non-Institutional category in terms of the RHP. If, however, the Bidder does not either revise the Bid or make additional payment and the Offer Price is higher than the cap of the Price Band prior to revision, the number of Equity Shares Bid for shall be adjusted downwards for the purpose of Allotment, such that no additional payment would be required to be blocked and the Bidder is deemed to have approved such revised Bid at Cut-off Price. (i) In case of a downward revision in the Price Band, announced as above, Retail Individual Bidders, who have bid at Cut-off Price could either revise their Bid or the excess amount blocked at the time of bidding would be unblocked from the ASBA Account after the Allotment is finalised.
5. Only the first Bidder is required to sign the Bid cum Application Form/Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. If the first applicant is not the account holder, ensure that the Bid cum Application Form is signed by the account holder.
6. **Other Instructions:** a. Revision to Bids must be made only in the prescribed Revision Form, as applicable. b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Syndicate Members/SCSBs/Collecting Agents/Registered Brokers/RTA/CDP will not be liable for errors in data entry due to incomplete or illegible Revision Forms. c. Ensure that Acknowledgement slip for your Bid has and any other applicable documents in support of the revision are attached with the Revision Form; and d. Bidders shall only be required to issue instructions to block the revised the amount in excess of their original Bid Amount (if any) upon an upward revision of their Bid.

OFFER STRUCTURE

Particulars	QIBs ^(a)	Non-Institutional Investors	Retail Individual Investors
Number of Equity Shares available for allocation/ Allotment [*]	At least 1,09,34,670 Equity Shares	Not more than 21,86,934 Equity Shares available for allocation	Not more than 14,57,956 Equity Shares available for allocation
Percentage of the Offer Size available for allocation/ Allotment	Not less than 75% of Net Offer Size shall be allocated to QIBs. However, up to 5% of the Net QIB Portion shall be available for allocation proportionately to Mutual Funds only. Up to 60% of the QIB Portion may be available for allocation to Anchor Investors and one- third of the Anchor Investor Portion shall be available for allocation to domestic Mutual Funds.**	Not more than 15% of the Net Offer.	Not more than 10% of the Net Offer.
Basis of allocation/ Allotment, if respective category is oversubscribed	Proportionate as follows: (a) 2,18,693 Equity Shares, constituting 5% of the Net QIB Portion (excluding Anchor Investor Portion), shall be available for allocation on a proportionate basis to Mutual Funds; (b) 41,55,175 Equity Shares shall be allotted on a proportionate basis to all QIBs (except to Anchor Investors) including Mutual Funds receiving allocation as per (a) above.	Proportionate.	Not less than the minimum Bid Lot (subject to availability of Equity Shares), and the remaining Equity Shares, if any, shall be allotted on a proportionate basis ^{##} .
Minimum Bid	Such number of Equity Shares and in multiples of [●] Equity Shares thereafter such that the Bid Amount exceeds ₹ 200,000.	Such number of Equity Shares that the Bid Amount exceeds ₹ 200,000 and in multiples of [●] Equity Shares thereafter.	[●] Equity Shares and in multiples of [●] Equity Shares thereafter.
Maximum Bid	Not exceeding the size of the Net Offer subject to Regulations as applicable to the Bidder.	Not exceeding the size of the Net Offer subject to regulations as applicable to the Bidder.	Such number of Equity Shares in multiples of [●] so as to ensure that the Bid Amount does not exceed ₹ 200,000.
Mode of bidding	Through ASBA only.	Through ASBA only.	Through ASBA only.
Mode of Allotment	Compulsorily in dematerialized form.	Compulsorily in dematerialized form.	Compulsorily in dematerialized form.
Bid Lot	[●] Equity Shares in multiples of [●] Equity Shares thereafter.	[●] Equity Shares in multiples of [●] Equity Shares thereafter.	[●] Equity Shares in multiples of [●] Equity Shares thereafter.
Allotment Lot	[●] Equity Shares and in multiples of one Equity Shares thereafter.	[●] Equity Shares and in multiples of one Equity Shares thereafter.	[●] Equity Shares and in multiples of one Equity Shares thereafter.
Trading Lot	One Equity Share.	One Equity Share.	One Equity Share.
Who can Apply***	Public financial institutions as specified in Section 2(72) of the Companies Act, 2013, Scheduled Commercial Banks, Mutual Fund registered with SEBI, FPIs other than Category III Foreign Portfolio Investors, VFCs, FVCIs, Multilateral and Bilateral Development Financial Institutions, State Industrial Development Corporation, Insurance Company registered with IRDA, provident fund (subject to applicable law) with minimum corpus of ₹ 2500 lacs, pension fund with minimum corpus of ₹ 2500 lacs, in accordance with applicable law and National Investment Fund set up by the Government of India, insurance funds set up and managed by army, navy or air force of the Union of India and insurance funds set up and managed by the Department of Posts, India	Resident Indian individuals, Eligible NRIs, HUFs (in the name of Karta), companies, corporate bodies, scientific Institutions societies and trusts, Category III FPIs	Resident Indian individuals, Eligible NRIs and HUFs (in the name of Karta).
Terms of Payment##	Full Bid Amount shall be payable at the time of submission of the Bid cum Application Form through the ASBA Process (other than for Anchor Investors).	Full Bid Amount shall be payable at the time of submission of the Bid cum Application Form through the ASBA Process.	Full Bid Amount shall be payable at the time of submission of the Bid cum Application Form through ASBA.

[@] Our Company and the Selling Shareholders may, in consultation with the BRLM, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is being done to other Anchor Investors. For details, please refer to the chapter "Offer Procedure" on page 208.

^{*} Subject to valid Bids being received at or above the Offer Price pursuant to the Net Offer is being made for at least 25% of the post-Offer paid-up Equity Share capital of our Company. The Offer is being made through the Book Building Process, wherein not less than 75% of the Net Offer will be available for allocation to QIBs on a proportionate basis, provided that our Company and the Selling Shareholders may, in consultation with the BRLM, allocate up to 60% of the QIB Portion to Anchor Investors at the Anchor Investor Offer Price to the Anchor Investor, on a discretionary basis subject to valid bids being received at Anchor Investor Offer Price. One-third of the Anchor Investor Portion shall be reserved for domestic mutual funds. Further, not more than 15% of the Net Offer will be available for allocation on a proportionate basis to Non-Institutional Investors, subject to valid Bids being received at or above the Offer Price and not more than 10% of the Net Offer will be available for allocation to Retail Individual Investors in accordance with SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Allotment of Equity Shares to each of the Retail Individual Investors shall not be less than the minimum Bid Lot, subject to availability of Equity Shares in the Retail Portion and the remaining available Equity Shares, if any, shall be allotted on a proportionate basis. Any unsubscribed portion in any reserved category, if any shall be added to the Net Offer. In case of under-subscription, if any, in Non-Institutional and Retail Individual categories, the under subscription would be allowed to be met with spill over inter-se from any other categories, at the discretion of our Company and Selling Shareholders in consultation with the BRLM and subject to applicable provisions of SEBI ICDR Regulations. However, under-subscription in the Net QIB Portion would not be allowed to be met with spill-over from any other category.

^{**} Full Bid Amount shall be payable by the Anchor Investors at the time of submission of the Bid cum Application Forms. In case the Anchor Investor Offer Price is lower than the Offer Price, the balance amount will be payable as per pay-in date mentioned in the revised CAN.

^{***} In case of joint Bids, the Bid cum Application Form should contain only the name of the First Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The signature of only such First Bidder would be required in the Bid cum Application Form and such First Bidder would be deemed to have signed on behalf of the joint holders. Bidders will be required to confirm and will be deemed to have represented to our Company, the BRLM, their respective directors, officers, agents, affiliates and representatives that they are eligible under applicable laws, rules, regulations, guidelines and approvals to acquire the Equity Shares in this Offer.

[#] In case of oversubscription in Retail Portion, maximum number of Retail Individual Investors who can be Allotted the minimum Bid Lot will be computed by dividing the total number of Equity Shares available for Allotment to Retail Individual Investors by the minimum Bid Lot ("Retail – Bid Lot Allottees"). The Allotment to Retail Individual Investors will then be made in the following manner:

- i. In the event the number of Retail Individual Investors who have submitted valid Bids in the Net Offer is equal to or less than Retail – Bid Lot Allottees, (i) all such Retail Individual Investors shall be Allotted the minimum Bid Lot; and (ii) the balance Equity Shares, if any, remaining in the Retail Portion shall be Allotted on a proportionate basis to those Retail Individual Investors who have applied for more than the minimum Bid Lot, for the balance demand of the Equity Shares Bid by them (i.e. the difference between the Equity Shares Bid and the minimum Bid Lot).
- ii. In the event number of Retail Individual Investors who have submitted valid Bids in the Net Offer is more than the Retail – Bid Lot Allottees, those Retail Individual Investors, who will be Allotted the minimum Bid Lot shall be determined the basis of draw of lots. In the event of a draw of lots, Allotment will only be made to such Retail Individual Investors who are successful pursuant to such draw of lots.

^{##} In case of ASBA Bidders, the SCSB shall be authorised to block such funds in the bank account of the ASBA Bidder that is specified in the Bid cum Application Form.

**COMMON
BID
REVISION FORM**

GREENSIGNAL BIO PHARMA LIMITED - INITIAL PUBLIC OFFER - NR

Regd and Corp. Off.: Old No. 5, New No. 13/A-3 Sai Niketan Circular Road, United India Colony, Kodambakkam, Chennai 600 024, Tamil Nadu, India.
Tel: +91 44 2472 2244; Facsimile: +91 44 2472 2233; Website: http://www.gsbl.com ; CIN: U24232TN2005PLC058068

**FOR NON-RESIDENTS, INCLUDING
ELIGIBLE NRIs, FIIs FPIs OR FVCIs, ETC
APPLYING ON A REPATRIATION BASIS**



To,
**The Board of Directors
GREENSIGNAL BIO PHARMA LIMITED**

BOOK BUILT OFFER

ISIN - INE811U01010

**Bid Cum
Application
Form No.**

SYNDICATE MEMBER'S STAMP & CODE	BROKER'S / SCSB / DP / RTA STAMP & CODE
SUB-BROKER'S/SUB-AGENT'S STAMP & CODE	ESCROW BANK / SCSB BRANCH STAMP & CODE
BANK BRANCH SERIAL NO.	SCSB SERIAL NO.

1. NAME & CONTACT DETAILS OF SOLE/FIRST BIDDER

Mr./Ms./M/s. _____

Address _____

Email _____

Tel. No (with STD code) / Mobile _____

2. PAN OF SOLE / FIRST BIDDER

3. BIDDERS DEPOSITORY ACCOUNT DETAILS ☐ NSDL ☐ CDSL

For NSDL enter 8 Digit DP ID followed by 8 Digit Client ID / For CDSL enter 16 Digit Client ID.

PLEASE CHANGE MY BID

4. FROM (AS PER LAST BID OR REVISION)

Bid Options	No. of Equity Shares Bid (Bids must be in multiples of Bid Lot as advertised) (in Figures)	Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1/- only) (In Figures)		
		Bid Price	Retail Discount, if any	Net Price
Option 1	8 7 6 5 4 3 2 1	4 3 2 1	3 2 1	4 3 2 1
(OR) Option 2				
(OR) Option 3				

5. TO (REVISED BID) (Only Retail individual Bidders and Eligible Employees Bidding in the Employee Reservation Portion can BID at "Cut-Off")

Bid Options	No. of Equity Shares Bid (in Figures) (Bids must be in multiples of Bid Lot as advertised)	Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1/- only) (In Figures)		
		Bid Price	Retail Discount, if any	Net Price
Option 1	8 7 6 5 4 3 2 1	4 3 2 1	3 2 1	4 3 2 1
(OR) Option 2				
(OR) Option 3				

6. PAYMENT DETAILS

PAYMENT OPTION : Full Payment ☐ Part Payment ☒

Additional Amount Blocked (₹ in Figures) _____ (₹ in words) _____

ASBA Bank A/c No. _____

Bank Name & Branch _____

I/WE (ON BEHALF OF JOINT APPLICANTS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS BID CUM APPLICATION FORM AND THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC OFFERS ("GID") AND HEREBY AGREE AND CONFIRM THE 'BIDDERS UNDERTAKING' AS GIVEN OVERLEAF. I/WE (ON BEHALF OF JOINT APPLICANTS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THE BID CUM APPLICATION FORM GIVEN OVERLEAF.

7 A. SIGNATURE OF SOLE / FIRST BIDDER	7 B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS)	SYNDICATE MEMBER/BROKER / SCSB / CDP / RTA STAMP (Acknowledging upload of Bid in Stock Exchange system)
Date: _____, 2016	I/We authorize the SCSB to do all acts as are necessary to make the Application in the Offer	
	1) _____	
	2) _____	
	3) _____	

TEAR HERE



**GREENSIGNAL BIO PHARMA LIMITED -
BID REVISION FORM -
INITIAL PUBLIC OFFER - NR**

**Acknowledgement Slip
for Syndicate Member
Broker/SCSB/CDP/RTA**

**Bid Cum
Application
Form No.**

PAN of Sole / First Bidder _____

DPID / CLID _____

Additional Amount Blocked (₹ in figures) _____ ASBA A/c. No. _____

Bank & Branch _____

Received from Mr./Ms. _____

Telephone / Mobile _____ Email _____

Stamp & Signature of SCSB Branch _____

TEAR HERE

GREENSIGNAL BIO PHARMA LIMITED - BID REVISION FORM - INITIAL PUBLIC OFFER - NR	Option 1	Option 2	Option 3	Stamp & Signature of Syndicate Member / Registered Broker / SCSB / CDP / RTA	Name of Sole / First Bidder
	No. of Equity Shares				
	Bid Price				
	Additional Amount Blocked (₹)				
ASBA Bank A/c No.: _____				Acknowledgment Slip for Bidder	
Bank & Branch: _____					
				Bid Cum Application Form No.	